Skip to content
Clinical Trials – home

Rare diseases

Investigational molecules

Locations

Our offerNewsroom

Recruiting

Study on the Effects of Octreotide in Reducing Blood Loss During Laparoscopic Liver Surgery for Patients Undergoing Hepatectomy

Verified siteRegistered drug
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

What is this trial about?

A plain-language summary of the goals, design and what participants do

This clinical trial is focused on studying the effects of a medication called octreotide during a type of liver surgery known as laparoscopic hepatectomy. This surgery involves removing part of the liver using small incisions and a camera to guide the procedure. The trial aims to observe how octreotide, which is a synthetic version of a natural hormone, affects blood loss during the surgery compared to a placebo. The study will also look at the need for medications that help control blood pressure and heart rate, as well as the requirement for blood transfusions during and after the surgery.

Participants in the study will receive either octreotide or a placebo during their surgery. The trial will monitor several factors, including the amount of blood lost, changes in heart rate and blood pressure, and the need for blood transfusions. Additionally, the study will assess liver function recovery after surgery and any complications that may arise up to three months post-surgery. The goal is to determine if octreotide can help reduce blood loss and improve overall outcomes for patients undergoing this type of liver surgery.

The trial will run until 2026, and it will provide valuable information on the safety and effectiveness of using octreotide in laparoscopic hepatectomy. By understanding how this medication impacts surgery outcomes, healthcare providers can make more informed decisions about its use in managing blood loss and other related factors during liver surgeries.

The research process

The trial runs in 6 steps – from screening to follow-up. Each step says what happens and what the team monitors.

  1. Step 1

    Joining the study

    Upon joining the study, consent is confirmed. Eligibility is based on being between 18 and 80 years old, having a diagnosis of hepatic lesions, and planning to undergo laparoscopic hepatectomy surgery. It is important to ensure no allergies to the medication used in the trial.

  2. Step 2

    Pre-surgery preparation

    Before the surgery, a detailed medical assessment is conducted to ensure readiness for the procedure. This includes reviewing medical history and current health status.

  3. Step 3

    Administration of medication

    During the surgery, the medication octreotide is administered. This is given as a solution for injection or infusion. The purpose is to observe its effects on blood loss during the surgery.

  4. Step 4

    Monitoring during surgery

    Throughout the surgery, monitoring of blood loss, heart rate, and blood pressure is conducted. The need for blood transfusions and use of additional medications to support blood pressure is assessed.

  5. Step 5

    Post-surgery observation

    After the surgery, recovery is monitored closely. This includes checking blood levels and liver function. Observations continue for 24 to 72 hours to ensure stability and address any immediate needs.

  6. Step 6

    Follow-up assessments

    Follow-up assessments are scheduled at discharge and three months post-surgery. These evaluations focus on recovery, liver function, and any complications that may arise.

Who can join the trial?

5 criteria

  • Patients diagnosed with hepatic lesions (liver problems) who are going to have laparoscopic hepatectomy (a type of liver surgery done with small cuts).
  • The patient must be between 18 and 80 years old.
  • The patient, or their representative, must have given consent to participate in the study.
  • The patient must be able, in the opinion of the investigator, to follow all the requirements of the clinical trial.
  • The patient must not be allergic to the drug used in the study.

Who cannot join the trial?

3 criteria

  • Patients who are not undergoing laparoscopic hepatectomy surgery cannot participate. This is a type of surgery to remove part of the liver using small cuts and a camera.
  • Patients who are not within the specified age range cannot participate. The study includes adults and older adults.
  • Patients who are part of a vulnerable population cannot participate. This means people who might be at higher risk of harm or exploitation.
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.

We usually reply within a few days

Verified sites

All sites with verified contact details – recruitment status may not be available; ask directly

Trial locations

Where you can join this trial

Countries are shaded by recruitment status. Click a recruiting country to ask about joining there.

Recruiting
Not finding your country?

Not sure what to do next?

Joining a clinical trial can seem overwhelming. We guide you step by step, so you know exactly what to expect and how we support you through the process.

See the full process and FAQ

Investigated drugs

Octreotide is a medication used in this clinical trial to help reduce blood loss during laparoscopic liver surgery. It works by mimicking a natural hormone in the body that can decrease the amount of blood flow to certain areas, which may help in reducing bleeding during surgery. This can potentially lessen the need for blood transfusions and the use of other medications to control blood pressure during the operation.

What is already known about the treatment

Octreotide – Octreotide is administered as an injection, typically under the skin or into a vein, and is currently being studied for its effects during laparoscopic hepatectomy surgery. It is primarily used to reduce blood loss during surgery, potentially decreasing the need for blood transfusions and vasoactive drugs. At the molecular level, octreotide works by mimicking a natural hormone in the body called somatostatin, which helps to reduce blood flow to certain areas and decrease the production of certain bodily fluids. It is classified as a somatostatin analog in pharmacology.

Investigated diseases

Liver Disease – Liver disease refers to any condition that affects the liver's ability to function properly. It can result from various factors, including infections, genetic conditions, or lifestyle choices such as alcohol consumption. As liver disease progresses, it can lead to inflammation, scarring (fibrosis), and eventually cirrhosis, where the liver becomes severely scarred and unable to function. Symptoms may include jaundice, fatigue, and abdominal pain. Over time, liver disease can impair the liver's ability to detoxify the blood, produce essential proteins, and regulate metabolism. The progression of liver disease can vary depending on the underlying cause and individual health factors.
Trial detailsLast updated 2 Oct 2026
Age18+ yearsPhasePhase IITrial ID2023-503613-29-00Protocol codeHEPA-OCTEstimated enrolment62 patientsSponsorClinica Universidad De Navarra

sourced from the EU Clinical Trials Register and site verification

Want to learn more about this trial or check if you can participate?

Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.

ClinicalTrials.eu

Every clinical trial in Europe, in plain language.

Explore the full ecosystem of clinical research in Europe.

Search trials

Legal notice · Published by CTIN POLAND sp. z o.o., ul. rtm. Witolda Pileckiego 67/109, 02-781 Warsaw, Poland · KRS 0001111334 · REGON 528919042 · NIP 9512598637

© 2026 Clinical Trials EU – European Clinical Trials Information Network

GDPR compliance, ISO 9001 and ISO 27001 certified (LL-C Certification)

On this site, “treatment” means an investigational medicine being studied in a clinical trial. Its safety and efficacy for the use being studied have not yet been confirmed, some participants may receive a placebo or a comparator medicine, and taking part does not guarantee any health benefit. The decision to take part is made by the doctor at the research site. This site is for information only and does not replace medical advice.

This service is not affiliated with the European Commission, the EMA, or the official CTIS system. Most information comes from publicly available international clinical-trial registries, supplemented by data from academic sites, national regulators and commercial sponsors. On this site, “treatment” and “therapy” mean a medicine being tested in a clinical trial. Its safety and effectiveness in the use being studied are not yet confirmed, some participants may receive a placebo or a comparator, and taking part does not guarantee a health benefit. The doctor at the research site decides who can take part. This site provides information, not medical advice. Certain content and visual elements on this website have been generated or enhanced using artificial intelligence (AI).